Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

NDAQ:AVXL) Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of ...

Aging involves gradual functional decline across various biological systems, including impaired cellular mechanisms such as ...

GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis, Inc., a pre-clinical biotech company transforming the treatment ...

Scientists have developed an advanced multi-organ model to deepen the understanding of the gut-brain connection in ...

Lisa Volenec was diagnosed with early-onset Parkinson's a decade ago. In recent months, she has realized the power of her own ...

An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day. About Anavex Life Sciences Corp.

Share on Pinterest Nadine Greeff/Stocksy United Parkinson’s disease affects nearly 1 million people in the United States, and the number of new diagnoses each year is rising. Symptoms vary from ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

IRX-4204 is under clinical development by Io Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...